Influenza Diagnostics Market: Segmented: By Test Type (Traditional Diagnostics Tests and Molecular Diagnostic Tests); By End-User (Hospitals, Clinical Laboratories, Research Centers, Point of Care Testing Centers and Other End User); By Type of Flu (Type A, Type B and Type C); and Region – Analysis of Market Size, Share & Trends for 2018 – 2020 and Forecasts to 2030
Global Influenza Diagnostics Market By Test Type (Traditional Diagnostics Tests and Molecular Diagnostic Tests); By End-User (Hospitals, Clinical Laboratories, Research Centers, Point of Care Testing Centers and Other End User); By Type of Flu (Type A, Type B and Type C); and Region - Analysis of Market Size, Share & Trends for 2018 - 2020 and Forecasts to 2030
PRODUCT OVERVIEW
Influenza is an infectious disease caused by the influenza virus, commonly known as the flu. Humans are affected by three types of this virus: type A, type B, and type C. Influenza spread through contagious respiratory secretions caused by the development of aerosols due to direct contact with an infected person. This virus can cause seasonal epidemics with increased morbidity and mortality levels so it is significant to diagnose such disease at an initial time. Such epidemics have been estimated to result in around 3 to 5 million annual cases of serious sickness, and about 250,000 to 500,000 annual deaths worldwide, according to WHO.
MARKET HIGHLIGHTS
Influenza Diagnostics Market is expected to project a CAGR of 6.10% during the forecast period, 2022-2032
Market growth is mainly driven by factors such as rising influenza occurrence, growth in research funding for influenza diagnosis, and increasing demand for faster diagnosis are the major factors expected to drive this market's growth in the coming years. High-risk influenza populations consist of pregnant women, infants, the elderly, immunosuppressed patients suffering from chronic medical conditions, and health care staff. Influenza treatment consists of different antiviral drugs that help to reduce complications and fatalities like death. In 2009, an influenza A pandemic, which spread rapidly to many nations, attracted scientists' attention to work on improved detection and diagnosis of the virus. Influenza diagnostics consists of several flu tests that are used in respiratory specimens to detect influenza viruses.
GLOBAL INFLUENZA DIAGNOSTICS MARKET: SEGMENTS
RIDT section held the largest share of the influenza diagnostic market for traditional diagnostic tests.
The large proportion of this section can be attributed to the rising adoption of cost-effective and faster RIDT as the first line of diagnosis and screening phase has been increased among end-users. These tests are antigen detection assays that detect influenza viral antigens within 10 to 15 minutes with high specificity. Rapid influenza diagnostic tests can identify the presence of influenza A and B viral antigens in respiratory samples and qualitatively exhibit the result. These tests are antigen detection assays that detect highly specific viral antigens of influenza within 10 to 15 minutes. It is a significant factor responsible for the largest share of the RIDT demand.
The segment of the hospital had dominated the largest share of the diagnostic influenza market in 2019.
The hospital segment is responsible for a substantial share of the diagnostic market for influenza in 2019, influenza disease diagnosis is usually conducted in hospitals because it is complicated and requires technologically advanced products, this is the major factor driving this segment’s growth in increased influenza-related hospitalizations. The hospital provides advanced facilities at an affordable price to conduct proper influenza diagnostic tests.
MARKET DYNAMICS
Drivers
Rising Population and Government Initiatives
Influenza Virus Mutating and Change in Virus Type
Restraints
Lack of Awareness and Healthcare Infrastructure
GLOBAL INFLUENZA DIAGNOSTICS MARKET: KEY PLAYERS
Global Influenza Diagnostics Market Segments:
PRODUCT OVERVIEW
Influenza is an infectious disease caused by the influenza virus, commonly known as the flu. Humans are affected by three types of this virus: type A, type B, and type C. Influenza spread through contagious respiratory secretions caused by the development of aerosols due to direct contact with an infected person. This virus can cause seasonal epidemics with increased morbidity and mortality levels so it is significant to diagnose such disease at an initial time. Such epidemics have been estimated to result in around 3 to 5 million annual cases of serious sickness, and about 250,000 to 500,000 annual deaths worldwide, according to WHO.
MARKET HIGHLIGHTS
Influenza Diagnostics Market is expected to project a CAGR of 6.10% during the forecast period, 2022-2032
Market growth is mainly driven by factors such as rising influenza occurrence, growth in research funding for influenza diagnosis, and increasing demand for faster diagnosis are the major factors expected to drive this market's growth in the coming years. High-risk influenza populations consist of pregnant women, infants, the elderly, immunosuppressed patients suffering from chronic medical conditions, and health care staff. Influenza treatment consists of different antiviral drugs that help to reduce complications and fatalities like death. In 2009, an influenza A pandemic, which spread rapidly to many nations, attracted scientists' attention to work on improved detection and diagnosis of the virus. Influenza diagnostics consists of several flu tests that are used in respiratory specimens to detect influenza viruses.
GLOBAL INFLUENZA DIAGNOSTICS MARKET: SEGMENTS
RIDT section held the largest share of the influenza diagnostic market for traditional diagnostic tests.
The large proportion of this section can be attributed to the rising adoption of cost-effective and faster RIDT as the first line of diagnosis and screening phase has been increased among end-users. These tests are antigen detection assays that detect influenza viral antigens within 10 to 15 minutes with high specificity. Rapid influenza diagnostic tests can identify the presence of influenza A and B viral antigens in respiratory samples and qualitatively exhibit the result. These tests are antigen detection assays that detect highly specific viral antigens of influenza within 10 to 15 minutes. It is a significant factor responsible for the largest share of the RIDT demand.
The segment of the hospital had dominated the largest share of the diagnostic influenza market in 2019.
The hospital segment is responsible for a substantial share of the diagnostic market for influenza in 2019, influenza disease diagnosis is usually conducted in hospitals because it is complicated and requires technologically advanced products, this is the major factor driving this segment’s growth in increased influenza-related hospitalizations. The hospital provides advanced facilities at an affordable price to conduct proper influenza diagnostic tests.
MARKET DYNAMICS
Drivers
Rising Population and Government Initiatives
Influenza Virus Mutating and Change in Virus Type
Restraints
Lack of Awareness and Healthcare Infrastructure
GLOBAL INFLUENZA DIAGNOSTICS MARKET: KEY PLAYERS
- Abbott Laboratories (including Alere)
- Quidel Corporation
- Genome Diagnostics
- Meridian Bioscience
- BioMerieux SA
- Sekisui Diagnostics
- Response Biomedical
- SA Scientific
- Enigma Diagnostics
- Focus Diagnostics
- Other Prominent Players
Global Influenza Diagnostics Market Segments:
- By Test Type
- Traditional Diagnostic Tests
- RIDT
- Viral Culture
- DFA
- Serological assays
- Molecular Diagnostic Tests
- RT-PCR
- INNATE
- TMA
- LAMP
- NASBA
- Other INNAT
- Other Molecular Tests
- By End-User
- Hospitals
- Clinical Laboratories
- Research Centers
- Point of Care Testing Centers.
- Other End-User
- By Type of Flu
- Type A Flu
- Type B Flu
- Type C Flu
- Global Influenza Diagnostics Market Dynamics
- Global Influenza Diagnostics Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
1. EXECUTIVE SUMMARY
2. INFLUENZA DIAGNOSTICS
2.1. Influenza Diagnostics Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MARKET DYNAMICS
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
7. RISK ANALYSIS
7.1. Demand Risk Analysis
7.2. Supply Risk Analysis
8. INFLUENZA DIAGNOSTICS INDUSTRY ANALYSIS
8.1. Porters Five Forces
8.1.1. The threat of New Entrants
8.1.2. Bargaining Power of Suppliers
8.1.3. Threat of Substitutes
8.1.4. Rivalry
8.2. PEST Analysis
8.2.1. Political
8.2.2. Economic
8.2.3. Social
8.2.4. Technological
9. GLOBAL INFLUENZA DIAGNOSTICS MARKET
9.1. Market Size & forecast, 2019A-2030F
9.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
9.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10. GLOBAL INFLUENZA DIAGNOSTICS MARKET: MARKET SEGMENTATION
10.1. By Regions
10.1.1. North America: (U.S. and Canada)
10.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
10.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
10.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
10.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.5. The Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
10.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2. By Test Type: Market Share (2020-2030F)
10.2.1. Traditional Diagnostics Tests, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2.2. Molecular Diagnostic Tests, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3. By Type of Flu: Market Share (2020-2030F)
10.3.1. Type A, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3.2. Type B, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3.3. Type C, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4. By End User: Market Share (2020-2030F)
10.4.1. Hospitals, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.2. Clinical Laboratories, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.3. Research Centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.4. Point of Care Testing Centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.5. Other End User, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. COMPANY PROFILE
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Company Total Revenue (Financials)
11.1.3. Market Potential
11.1.4. Global Presence
11.1.5. Key Performance Indicators
11.1.6. SWOT Analysis
11.1.7. Product Launch
11.2. Siemens Healthineers
11.3. Analytik Jena
11.4. Quidel Corporation
11.5. Genome Diagnostics
11.6. Meridian Bioscience
11.7. BioMerieux SA
11.8. Sekisui Diagnostics
11.9. Response Biomedical
11.10. SA Scientific
11.11. Enigma Diagnostics
11.12. Focus Diagnostics
Consultant Recommendation
The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. INFLUENZA DIAGNOSTICS
2.1. Influenza Diagnostics Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MARKET DYNAMICS
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
7. RISK ANALYSIS
7.1. Demand Risk Analysis
7.2. Supply Risk Analysis
8. INFLUENZA DIAGNOSTICS INDUSTRY ANALYSIS
8.1. Porters Five Forces
8.1.1. The threat of New Entrants
8.1.2. Bargaining Power of Suppliers
8.1.3. Threat of Substitutes
8.1.4. Rivalry
8.2. PEST Analysis
8.2.1. Political
8.2.2. Economic
8.2.3. Social
8.2.4. Technological
9. GLOBAL INFLUENZA DIAGNOSTICS MARKET
9.1. Market Size & forecast, 2019A-2030F
9.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
9.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10. GLOBAL INFLUENZA DIAGNOSTICS MARKET: MARKET SEGMENTATION
10.1. By Regions
10.1.1. North America: (U.S. and Canada)
10.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
10.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
10.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
10.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.5. The Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
10.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2. By Test Type: Market Share (2020-2030F)
10.2.1. Traditional Diagnostics Tests, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2.2. Molecular Diagnostic Tests, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3. By Type of Flu: Market Share (2020-2030F)
10.3.1. Type A, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3.2. Type B, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3.3. Type C, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4. By End User: Market Share (2020-2030F)
10.4.1. Hospitals, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.2. Clinical Laboratories, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.3. Research Centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.4. Point of Care Testing Centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.5. Other End User, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. COMPANY PROFILE
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Company Total Revenue (Financials)
11.1.3. Market Potential
11.1.4. Global Presence
11.1.5. Key Performance Indicators
11.1.6. SWOT Analysis
11.1.7. Product Launch
11.2. Siemens Healthineers
11.3. Analytik Jena
11.4. Quidel Corporation
11.5. Genome Diagnostics
11.6. Meridian Bioscience
11.7. BioMerieux SA
11.8. Sekisui Diagnostics
11.9. Response Biomedical
11.10. SA Scientific
11.11. Enigma Diagnostics
11.12. Focus Diagnostics
Consultant Recommendation
The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
